Pharma pricing strategy aduhelm effect

What the Aduhelm backlash may mean for pharma pricing in the ‘new normal’

Learn how POLI can be used to identify new opportunities, plan for risks, and navigate the market access and pricing and reimbursement landscape.

The ongoing controversy over Biogen’s Aduhelm treatment shows that pricing scrutiny has risen to a new level.

The backlash after Biogen set the annual price for the drug at $56,000 – more than five times higher than analyst estimates – was immediate, and exacerbated criticism over the treatment’s uncertain efficacy.

With many countries still struggling to bring their economies back on track, policymakers are already looking more aggressively to contain costs. Drug prices are among the main targets.

Advanced analysis on price and reimbursement policy trends, in-depth market data, risk assessment scoring, and other key tools can help market access and planning professionals make informed global pricing decisions. This approach positions drug makers with data-based rationales for pricing decisions and brings greater transparency to the costs involved in the drug development pipeline.

Use POLI Strat to identify new opportunities, plan for risks, and navigate the market access and pricing and reimbursement landscape.

Stay up to date on the biggest trends impacting pharma markets and pricing in 2021 and beyond in our latest whitepaper.